Gilead Sciences (NASDAQ:GILD) is the most pharmaceutical company spoken about these days, with its antiviral remdesivir drug being the hottest drug at the moment according to its apparent success in clinical trials with patients who have COVID-19.
On Saturday, The U.S. Department of Health and Human Services (HHS) said it'll allow the state health departments to distribute Gilead Sciences Inc (NASDAQ:GILD)'s remdesivir drug to help fight the COVID-19, and that the U.S. is said to receive 40% of the global donations made by the drugmaker.
Gilead Sciences Inc (GILD) is down by $0.12, or by -0.15%, at $77.49.